title: Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients.
abstract: OBJECTIVE
  Clomethiazole is a neuroprotective drug that enhances gamma-aminobutyrate type A (GABA(A)) receptor activity. Its efficacy and safety were tested in the CLomethiazole Acute Stroke Study (CLASS). The protocol allowed a CT scan to be done after randomization but within 7 days of stroke onset to minimize delays before start of treatment. Ninety-five of the 1360 patients randomized were diagnosed as having intracranial hemorrhage rather than ischemic stroke. Safety results for clomethiazole compared with placebo in this group are reported.
  
  
  METHODS
  The study included patients with a clinical diagnosis of acute hemispheric cerebral infarction. Treatment was a 24-hour intravenous infusion of 75 mg/kg clomethiazole or placebo. Patients with intracranial hemorrhage discovered on a postrandomization CT were withdrawn from study treatment if treatment was ongoing, and all patients were followed up to 90 days.
  
  
  RESULTS
  Ninety-four patients received treatment, 47 in each group. The hemorrhage was classified as intracerebral in 89 patients (94%). Mortality at 90 days was 19.1% in the clomethiazole group and 23.4% in the placebo group. Sedation was the most common adverse event, occurring at a higher incidence in clomethiazole-treated patients (clomethiazole 53%, placebo 17%), followed by rhinitis and coughing. The incidence and pattern of serious adverse events was similar between the treatment groups. The percentage of patients reaching relative functional independence on the Barthel Index (score >/=60) at 90 days was 59.6% in the clomethiazole group and 53.2% in the placebo group.
  
  
  CONCLUSIONS
  Clomethiazole appears safe to administer to hemorrhagic stroke patients compared with placebo. These results would obviate the need for a CT scan before therapy is initiated in acute stroke. The safety of clomethiazole in hemorrhagic stroke patients will be further evaluated in a prospective study that is under way in North America.
authors.affiliation: Stroke Research Unit, Department of Neurology, Karolinska Hospital, Stockholm, Sweden. nilsgw@neuro.ks.se
authors.forename: N G
authors.initials: NG
authors.lastname: Wahlgren
authors.forename: E
authors.initials: E
authors.lastname: Díez-Tejedor
authors.forename: J
authors.initials: J
authors.lastname: Teitelbaum
authors.forename: A
authors.initials: A
authors.lastname: Arboix
authors.forename: D
authors.initials: D
authors.lastname: Leys
authors.forename: T
authors.initials: T
authors.lastname: Ashwood
authors.forename: E
authors.initials: E
authors.lastname: Grossman
mesh_terms: D000208:Acute Disease; D000368:Aged; D002719:Chlormethiazole / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D020300:Intracranial Hemorrhages / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D018696:Neuroprotective Agents; D002719:Chlormethiazole